SYMBIOTEC PHARMALAB LTD (SYMBIOTEC): SYMBIOTEC PHARMALAB Share Price rises 5.37% as stock trades higher today

SYMBIOTEC Share Price is trading at Rs 1,136.85, up 5.37% today, with market capitalisation at Rs 6,932.91 crore. The move keeps SYMBIOTEC PHARMALAB LTD in focus in today’s stock market update and among stocks in news. According to latest Univest data, the company’s price rise is clear, but a company-specific catalyst is not confirmed from the verified market record. That makes the current setup relevant for investors who are tracking the share price rise, the healthcare sector backdrop and the stock’s valuation profile. Univest data also shows the counter opened at Rs 1,066.05, touched a low of Rs 1,066.05 and a high of Rs 1,140.00, placing today’s move in a firmly positive price action zone.

For readers searching SYMBIOTEC Share Price Today, SYMBIOTEC Stock News and SYMBIOTEC Share News, the key point is straightforward: the stock is gaining today on measurable market action, while the latest Univest figures point to rich valuation metrics that deserve attention alongside the move.

SYMBIOTEC Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,136.85
Previous Close	Rs 1,078.95
Today's Move	Rs 57.9 (+5.37%)
Open	Rs 1,066.05
High	Rs 1,140
Low	Rs 1,066.05
Turnover	Rs 28.14 crore
Market Capitalisation	Rs 6,932.91 crore
Market Cap Category	Mid Cap

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) rose to Rs 1,136.85 from the previous close of Rs 1,078.95, a move of Rs 57.9 or 5.37%. The stock opened at Rs 1,066.05, reached a high of Rs 1,140, recorded a low of Rs 1,066.05.

SYMBIOTEC Share Price rose Rs 57.90 from the previous close of Rs 1,078.95 to Rs 1,136.85, a gain of 5.37% in today’s share market today session. The stock opened at Rs 1,066.05 and moved up to a high of Rs 1,140.00, showing that buyers remained active after the opening trade. Turnover stood at Rs 28.14 crore, which adds context to the day’s price action without changing the central fact: SYMBIOTEC Share Price is trading higher and drawing attention as one of the notable market movers in healthcare today.

This is the most relevant takeaway for SYMBIOTEC Share Price Live tracking right now. The latest movement confirms a strong share price update, but the verified record does not establish a company-specific catalyst for why the stock is rising today.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 6,932.91 crore
P/E Ratio	63.08x
P/B Ratio	4.67x
ROE	11.22%
ROCE	12.41%
EPS	Rs 17.1
Book Value Per Share	Rs 231.19
Dividend Yield	0%

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 63.08x, P/B 4.67x, ROE 11.22%, ROCE 12.41%. These figures provide context only and are not a buy or sell signal.

SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 6932.91 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 63.08x, P/B at 4.67x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 231.19, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.83x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	63.08x
Benchmark Median P/E	32.83x
Benchmark Average P/E	48.79x
Benchmark P/E Range	3.2x to 659.73x
Company P/B Ratio	4.67x
Benchmark Median P/B	2.92x
Company ROE	11.22%
Benchmark Median ROE	11.78%
Company ROCE	12.41%
Benchmark Median ROCE	13.65%
Company Market Capitalisation	Rs 6,932.91 crore
Benchmark Median Market Cap	Rs 674.09 crore

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 63.08x, which is above the benchmark median of 32.83x, a difference of +92.14%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.78%, a difference of -4.75%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.65%, a difference of -9.08%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries Ltd.	SUNPHARMA	4,55,633.71	37.67	5.27	14.85	19.11
Divi's Laboratories Ltd.	DIVISLAB	2,41,576.41	82.59	13.68	16.19	21.51
Torrent Pharmaceuticals Ltd.	TORNTPHARM	1,84,478.41	84.58	20.55	26.76	19.27
Cipla Ltd.	CIPLA	1,11,888.39	33.19	3.18	11.83	16
Zydus Lifesciences Ltd.	ZYDUSLIFE	1,11,820.18	24.78	4.15	19.69	21.39

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 63.08x compared with the displayed peer median of 37.67x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.22% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 6,932.91 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching SYMBIOTEC

• SYMBIOTEC Share Price is rising today by 5.37%, keeping the stock in focus during a positive market update.
• The stock traded between Rs 1,066.05 and Rs 1,140.00, which highlights the day’s price action clearly.
• Valuation remains elevated, with a P/E of 63.08 and P/B of 4.67 shaping the fundamental discussion.
• ROE of 11.22% and ROCE of 12.41% give context to the company’s returns profile.
• Healthcare sector comparisons show SYMBIOTEC Share Price is being assessed against a broad peer universe of 204 companies.

About SYMBIOTEC PHARMALAB LTD

SYMBIOTEC PHARMALAB LTD operates in Pharmaceuticals & Drugs within the Healthcare sector. The company’s market position is better understood through its financial ratios and market capitalisation than through a broad consumer-facing story in the latest record. Based on the latest Univest figures, investors are tracking SYMBIOTEC Share Price because the business is valued at Rs 6,932.91 crore, with EPS of 17.1, book value of Rs 231.19 and no dividend yield support.

The company’s share price performance today has brought its valuation and return ratios into sharper focus. For readers following SYMBIOTEC News Today, that means the most useful lens is not only the day’s gain but also how the company fits inside the pharmaceuticals landscape, where peer multiples and sector averages differ widely. Univest tracks these company, sector and market details so that the stock story remains grounded in verifiable financial context.

Frequently Asked Questions

Why is SYMBIOTEC Share Price rising today?

Ans. SYMBIOTEC Share Price is up 5.37% today, moving from Rs 1,078.95 to Rs 1,136.85. The verified record confirms the price rise, but it does not establish a company-specific catalyst.

What is the current SYMBIOTEC Share Price Today?

Ans. SYMBIOTEC Share Price Today is Rs 1,136.85. The stock opened at Rs 1,066.05 and touched Rs 1,140.00, showing a positive intraday move on the latest market update. The previous close was Rs 1,078.95.

How much has SYMBIOTEC Share Price gained today?

Ans. SYMBIOTEC Share Price has gained Rs 57.90 today, equal to 5.37%. That rise came alongside turnover of Rs 28.14 crore and a market capitalisation of Rs 6,932.91 crore.

What does SYMBIOTEC Share Price tell investors about valuation?

Ans. SYMBIOTEC Share Price reflects a P/E of 63.08 and P/B of 4.67. Those levels sit above the industry median and average, so valuation is a central part of the stock discussion.

How do SYMBIOTEC fundamentals look today?

Ans. SYMBIOTEC fundamentals include ROE of 11.22%, ROCE of 12.41%, EPS of 17.1 and book value of Rs 231.19. Dividend yield is 0, so payout support is not part of the current story.

How does SYMBIOTEC compare with pharma peers?

Ans. SYMBIOTEC Share Price is trading with a higher P/E than Cipla, Zydus Lifesciences and Lupin, but below Divi’s Laboratories and Torrent Pharmaceuticals. Its returns are mid-range versus the peer set.

What sector does SYMBIOTEC belong to?

Ans. SYMBIOTEC belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. Its latest move matters because sector valuation, size and profitability benchmarks shape how investors read SYMBIOTEC Share Price.

Should investors track SYMBIOTEC Share Price on Univest?

Ans. Yes, investors can track SYMBIOTEC Share Price on Univest for live updates, fundamentals, market cap, EPS, book value and peer context. It is a practical way to follow the stock’s market behaviour.

Track SYMBIOTEC Share Price on Univest

Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

You can track SYMBIOTEC Share Price on Univest for live share price updates, SYMBIOTEC Stock News, fundamental ratios, company overview, market capitalisation, EPS, book value, dividend yield and peer comparison. Univest also helps readers follow SYMBIOTEC Share Price Today alongside broader market insights and sector context. For investors using SYMBIOTEC Stock Analysis as part of their daily review, Univest provides a single place to monitor the stock, its valuations and its latest market action.